EKEdward R. Kost

Edward R. Kost

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Edward R. Kost has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ERX-208 Induces Endoplasmic Reticulum Stress and Suppresses DNA Damage Repair to Enhance Chemotherapy Sensitivity

    by Durga Meenakshi Panneerdoss, Khaled Mohamed Nassar, Baskaran Subramani, William Cole Arnold, Sai Pranathi Vedagiri Venkata, Joe Hernandez, Behnam Ebrahimi, Sonal R. Chaudhari, Gaurav Sharma, Tae-Kyung Lee, et al.

    Ovarian cancer remains the most lethal gynecologic malignancy, driven in part by intrinsic and acquired therapeutic resistance to DNA-damaging chemotherapies. We previously demonstrated that ERX-208 targets the protein encoded by lysosomal acid lipase to induce catastrophic endoplasmic reticulum (ER) stress in ovarian cancer models. As ERX-class compounds advance to clinical development, rational combination strategies are needed to maximize therapeutic efficacy. To address this question, we conducted an unbiased in vitro screen of the combination of ERX-208 with 147 FDA-approved agents. We identified that DNA-damaging chemotherapies, including anthracyclines, oxaliplatin, and paclitaxel, were most synergistic in combination with ERX-208. Reanalysis of our transcriptomic data in ovarian cancer cells revealed coordinated suppression of DNA damage repair, DNA replication, and checkpoint pathways following ERX-208 treatment. Together, these data support a narrative that ERX-208 may selectively suppress DNA repair pathways and potentiate cytotoxicity by DNA-damaging agents. To test this hypothesis, we used platinum and paclitaxel, two standard-of-care agents in ovarian cancer. We found that ERX-208 synergized with platinum and paclitaxel across multiple ovarian cancer models, enhancing apoptosis and suppressing proliferation, clonogenicity, and invasion. Mechanistically, combination treatment increased DNA damage and amplified ER stress and apoptotic signaling. Importantly, ERX-208–based combinations showed enhanced antitumor activity in patient-derived explant, and xenograft models. These findings support a model in which ERX-208 impairs DNA damage response pathways and sensitizes ovarian cancer cells to DNA-damaging chemotherapy. Collectively, these findings provide a strong rationale for the combination strategy in clinical translation. Significance: This study demonstrates the clinical utility of ERX-208 in enhancing chemotherapy efficacy in ovarian cancer. By inducing sustained ER stress and a functional DNA repair–deficient state, ERX-208 sensitizes treatment-naïve and treatment-resistant tumors to platinum and taxanes. Findings support the rapid clinical development of ERX-class combinations, offering a rationale for pairing with standard regimens. This strategy may enable dose reduction, overcome resistance, expand options, and support biomarker-guided patient selection.

  • Regional and statewide hysterectomy-corrected endometrial cancer incidence and five-year relative survival in Texas

    by Akemi T. Wijayabahu, Nicolas Wentzensen, Nameer B. Kirma, Lillian Lin-Smith, Wayne R. Lawrence, Chen-Pin Wang, Edward R. Kost


  • Open Access

    Regional and Statewide Hysterectomy-Corrected Endometrial Cancer Incidence and Five-Year Relative Survival in Texas

    by Akemi T. Wijayabahu, Nicolas Wentzensen, Nameer B. Kirma, Lillian Lin-Smith, Wayne R. Lawrence, Chen-Pin Wang, Edward R. Kost

    Background: Rising endometrial cancer (EC) incidence nationwide, particularly among Hispanic women, and high prevalence of risk factors such as obesity and comorbidities in Texas, motivated us to estimate EC incidence rates (IRs) and survival by age (<50 year early-onset, ≥50 year late-onset), race-ethnicity (Non-Hispanic-White [NHW], -Black [NHB], Hispanic), histology (endometrioid, non-endometrioid), and area-based socioeconomic (SES) factors across Texas Health Service Regions (HSRs).Study Design: Between 2000-2019, a total of 42,571 women (20-79 years) with EC were reported from Texas within the Surveillance, Epidemiology, and End Results Program. IRs and 5-year relative survival were calculated using SEER*Stat. IRs were corrected for hysterectomy using Behavioral Risk Factor Surveillance System data.Results: Statewide EC IRs rose from 38.8 (2000-2009) to 44.5 (2010-2019), with the highest increase in the Upper-South (42.6 to 53.8). Across HSRs, Upper-South consistently had higher IRs among women <50 (13.9) and ≥50 years (112.7). Among those <50 years, Hispanics had the highest IRs (12.4), predominantly endometrioid tumors, whereas in women ≥50 years, NHB had the highest IRs (119.2) with a large proportion of non-endometrioid tumors. IRs were higher in areas with lower poverty, and higher education, income, and urbanization. Associations with unemployment were mixed. Worse survival outcomes were observed among NHBs, non-endometrioid, advanced-stage, and lower SES. Central Texas had more favorable survival outcomes compared to other HSR.Conclusion: EC IRs and survival rates in Texas largely mirror national trends, with regional differences likely reflecting sociodemographic and histologic distributions.

  • Open Access

    EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling

    by William C. Arnold, Durga Meenakshi Panneerdoss, Baskaran Subramani, Megharani Mahajan, Behnam Ebrahimi, Paulina Ramirez, Bindu Santhamma, Suryavathi Viswanadhapalli, Edward R. Kost, Yidong Chen, et al.

    Ovarian cancer (OCa) remains the most lethal gynecologic malignancy in the United States, with low-grade serous and mucinous subtypes frequently driven by KRAS mutations. These mutations activate downstream MAPK and PI3K/AKT signaling pathways, contributing to tumor progression and resistance to therapy. Although the MEK inhibitor trametinib is used to target these pathways, its efficacy is limited in KRAS-mutant OCa due to compensatory activation of the leukemia inhibitory factor (LIF)/LIF receptor (LIFR) axis. In this study, we evaluated the therapeutic potential of combining trametinib with EC359, a selective LIFR inhibitor, in Ras/Raf-driven OCa models. EC359 significantly reduced cell viability, clonogenic survival, and induced cell death via ferroptosis in vitro. Mechanistic studies revealed that EC359 suppressed trametinib-induced activation of LIFR downstream signaling. RNA-seq analysis showed that combination therapy downregulated mitochondrial translation and MYC target genes while upregulating apoptosis-related genes. In vivo, EC359 and trametinib co-treatment significantly reduced tumor growth in xenograft and PDX models without inducing toxicity. Our studies identify LIFR signaling as a critical vulnerability in Ras/Raf-mutant and low grade serous OCa. Further, it provides strong preclinical rationale for EC359 and trametinib combination therapy as a new therapeutic strategy for treating Ras/Raf-driven OCa and low-grade serous OCa.

  • Open Access

    Saturation of respiratory strain during robotic hysterectomy in obese women with endometrial cancer

    by Edward R. Kost, Martin W. Goros, Paulina R. Ramirez, Devin B. Burroughs, Jonathan A. Gelfond, Georgia A. McCann

    To evaluate intraoperative ventilatory mechanics during robotic-assisted hysterectomy in obese women with endometrial cancer and introduce the concept of a physiologic “ceiling effect” in respiratory strain. We conducted a retrospective cohort study of 89 women with biopsy-confirmed endometrial cancer who underwent robotic-assisted total hysterectomy between 2011 and 2015. Intraoperative ventilatory parameters, including plateau airway pressure and static lung compliance, were recorded at five-minute intervals. Each patient’s peak plateau pressure was identified to calculate static compliance and estimate maximum ventilatory strain. Patients were stratified by body mass index (BMI), and ventilatory parameters were compared across BMI categories at baseline (post-induction, supine) and during steep Trendelenburg positioning with carbon dioxide pneumoperitoneum. At baseline, increasing BMI was significantly associated with higher plateau airway pressure and lower static compliance. For example, plateau pressure increased from 18.6 ± 3.4 cm of water (cm H₂O) in patients with BMI less than 30 kg per square meter to 25.9 ± 3.3 cm H₂O in those with BMI greater than or equal to 50 (p < 0.001). However, following Trendelenburg positioning with pneumoperitoneum, peak plateau pressures converged across BMI categories, averaging 35.0 ± 3.3 cm H₂O (p = 0.167). Static compliance also converged across BMI strata, averaging 17.2 ± 4.2 ml per cm H₂O (p = 0.129). Pulmonary complications occurred in 4.5% of patients, with no cases of barotrauma or prolonged mechanical ventilation. Intraoperative ventilatory strain appears driven primarily by surgical positioning and pneumoperitoneum, rather than obesity alone. These findings support the feasibility and safety of robotic-assisted hysterectomy across a wide range of body mass index values and introduce the novel concept of a physiologic ceiling effect in ventilatory stress.


  • Open Access

    Significance of LIF/LIFR Signaling in the Progression of Obesity-Driven Triple-Negative Breast Cancer

    by Lois Randolph, Jaitri Joshi, Alondra Lee Rodriguez Sanchez, Uday P. Pratap, Rahul Gopalam, Yidong Chen, Zhao Lai, Bindu Santhamma, Edward R. Kost, Hareesh B. Nair, et al.

    American women with obesity have an increased incidence of triple-negative breast cancer (TNBC). The impact of obesity conditions on the tumor microenvironment is suspected to accelerate TNBC progression; however, the specific mechanism(s) remains elusive. This study explores the hypothesis that obesity upregulates leukemia inhibitory factor receptor (LIFR) oncogenic signaling in TNBC and assesses the efficacy of LIFR inhibition with EC359 in blocking TNBC progression. TNBC cell lines were co-cultured with human primary adipocytes, or adipocyte-conditioned medium, and treated with EC359. The effects of adiposity were measured using cell viability, colony formation, and invasion assays. Mechanistic studies utilized RNA-Seq, Western blotting, RT-qPCR, and reporter gene assays. The therapeutic potential of EC359 was tested using xenograft and patient-derived organoid (PDO) models. The results showed that adipose conditions increased TNBC cell proliferation and invasion, and these effects correlated with enhanced LIFR signaling. Accordingly, EC359 treatment reduced cell viability, colony formation, and invasion under adipose conditions and blocked adipose-mediated organoid growth and TNBC xenograft tumor growth. RNA-Seq analysis identified critical pathways modulated by LIF/LIFR signaling in diet-induced obesity mouse models. These findings suggest that adiposity contributes to TNBC progression via the activation of the LIF/LIFR pathway, and LIFR inhibition with EC359 represents a promising therapeutic approach for obesity-associated TNBC.


  • Open Access

    Novel LIPA-Targeted Therapy for Treating Ovarian Cancer

    by Alexia B. Collier, Suryavathi Viswanadhapalli, Rahul Gopalam, Tae-Kyung Lee, Kara Kassees, Karla Parra, Gaurav Sharma, Tanner C. Reese, Xihui Liu, Xue Yang, et al.

    Ovarian cancer (OCa) is the most lethal form of gynecologic cancer, and the tumor heterogeneities at the molecular, cellular, and tissue levels fuel tumor resistance to standard therapies and pose a substantial clinical challenge. Here, we tested the hypothesis that the heightened basal endoplasmic reticulum stress (ERS) observed in OCa represents an exploitable vulnerability and may overcome tumor heterogeneity. Our recent studies identified LIPA as a novel target to induce ERS in cancer cells using the small molecule ERX-41. However, the role of LIPA and theutility of ERX-41 to treat OCa remain unknown. Expression analysis using the TNMplot web tool, TCGA data sets, and immunohistochemistry analysis using a tumor tissue array showed that LIPA is highly expressed in OCa tissues, compared to normal tissues. ERX-41 treatment significantly reduced the cell viability and colony formation ability and promoted the apoptosis of OCa cells. Mechanistic studies revealed a robust and consistent induction of ERS markers, including CHOP, elF2α, PERK, and ATF4, upon ERX-41 treatment. In xenograft and PDX studies, ERX-41 treatment resulted in a significant reduction in tumor growth. Collectively, our results suggest that ERX-41 is a novel therapeutic agent that targets the LIPA with a unique mechanism of ERS induction, which could be exploited to treat heterogeneity in OCa.


  • Open Access

    The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling

    by Nicole Spencer, Alondra Lee Rodriguez Sanchez, Rahul Gopalam, Panneerdoss Subbarayalu, Daisy M. Medina, Xue Yang, Paulina Ramirez, Lois Randolph, Emily Jean Aller, Bindu Santhamma, et al.

    Endometrial cancer (ECa) is the most common female gynecologic cancer. When comparing the two histological subtypes of endometrial cancer, Type II tumors are biologically more aggressive and have a worse prognosis than Type I tumors. Current treatments for Type II tumors are ineffective, and new targeted therapies are urgently needed. LIFR and its ligand, LIF, have been shown to play a critical role in the progression of multiple solid cancers and therapy resistance. The role of LIF/LIFR in the progression of Type II ECa, on the other hand, is unknown. We investigated the role of LIF/LIFR signaling in Type II ECa and tested the efficacy of EC359, a novel small-molecule LIFR inhibitor, against Type II ECa. The analysis of tumor databases has uncovered a correlation between diminished survival rates and increased expression of leukemia inhibitory factor (LIF), suggesting a potential connection between altered LIF expression and unfavorable overall survival in Type II ECa. The results obtained from cell viability and colony formation assays demonstrated a significant decrease in the growth of Type II ECa LIFR knockdown cells in comparison to vector control cells. Furthermore, in both primary and established Type II ECa cells, pharmacological inhibition of the LIF/LIFR axis with EC359 markedly decreased cell viability, long-term cell survival, and invasion, and promoted apoptosis. Additionally, EC359 treatment reduced the activation of pathways driven by LIF/LIFR, such as AKT, mTOR, and STAT3. Tumor progression was markedly inhibited by EC359 treatment in two different patient-derived xenograft models in vivo and patient-derived organoids ex vivo. Collectively, these results suggest LIFR inhibitor EC359 as a possible new small-molecule therapeutics for the management of Type II ECa.


  • Open Access

    Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth

    by Logan Blankenship, Uday P. Pratap, Xue Yang, Zexuan Liu, Kristin A. Altwegg, Bindu Santhamma, Kumaraguruparan Ramasamy, Swapna Konda, Yidong Chen, Zhao Lai, et al.

    Endometrial cancer (EC) is the fourth most common cancer in women, and half of the endometrioid EC (EEC) cases are attributable to obesity. However, the underlying mechanism(s) of obesity-driven EEC remain(s) unclear. In this study, we examined whether LIF signaling plays a role in the obesity-driven progression of EEC. RNA-seq analysis of EEC cells stimulated by adipose conditioned medium (ADP-CM) showed upregulation of LIF/LIFR-mediated signaling pathways including JAK/STAT and interleukin pathways. Immunohistochemistry analysis of normal and EEC tissues collected from obese patients revealed that LIF expression is upregulated in EEC tissues compared to the normal endometrium. Treatment of both primary and established EEC cells with ADP-CM increased the expression of LIF and its receptor LIFR and enhanced proliferation of EEC cells. Treatment of EEC cells with the LIFR inhibitor EC359 abolished ADP-CM induced colony formation andcell viability and decreased growth of EEC organoids. Mechanistic studies using Western blotting, RT-qPCR and reporter assays confirmed that ADP-CM activated LIF/LIFR downstream signaling, which can be effectively attenuated by the addition of EC359. In xenograft assays, co-implantation of adipocytes significantly enhanced EEC xenograft tumor growth. Further, treatment with EC359 significantly attenuated adipocyte-induced EEC progression in vivo. Collectively, our data support the premise that LIF/LIFR signaling plays an important role in obesity-driven EEC progression and the LIFR inhibitor EC359 has the potential to suppress adipocyte-driven tumor progression.